Emmes, a United States-based full-service Clinical Research Organisation, announced on Monday1, that it has named Dr Paul VanVeldhuisen as the president of Emmes Public Sector.
Dr VanVeldhuisen has more than 25 years of experience in clinical research. He joined Emmes in 1993 and later became a principal investigator. He has held roles of increasing responsibility in the company. Dr VanVeldhuisen has a PhD in epidemiology from The George Washington University, an MS in biostatistics from the University of Washington and a BS in mathematics from Calvin University.
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer